GLP1R and type 2 diabetes mellitus: ADA and EASD recommend GLP-1 RAs as a preferred first injectable therapy before insulin in most patients with T2DM who require intensification beyond oral agents, due to their efficacy in lowering HbA1c, low risk of hypoglycemia, and favorable effects on weight [38,40].